Citadel Advisors
SGMO

Citadel Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Citadel Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,208,415
Closed -$641K – 13933
2025
Q3 		$814K Buy
1,208,415
+1,013,154
+519% +$546K ﹤0.01% 7992
2025
Q2 		$106K Sell
195,261
-185,586
-49% -$110K ﹤0.01% 11292
2025
Q1 		$250K Sell
380,847
-423,467
-53% -$448K ﹤0.01% 9991
2024
Q4 		$820K Buy
804,314
+77,257
+11% +$141K ﹤0.01% 7458
2024
Q3 		$630K Buy
727,057
+246,121
+51% +$180K ﹤0.01% 7776
2024
Q2 		$172K Buy
480,936
+429,044
+827% +$232K ﹤0.01% 10149
2024
Q1 		$34.8K Sell
51,892
-1,179,404
-96% -$855K ﹤0.01% 12543
2023
Q4 		$669K Sell
1,231,296
-3,301,619
-73% -$1.52M ﹤0.01% 7493
2023
Q3 		$2.72M Buy
4,532,915
+37,902
+0.8% +$40.6K ﹤0.01% 4665
2023
Q2 		$5.84M Buy
4,495,013
+1,261,863
+39% +$1.72M ﹤0.01% 3409
2023
Q1 		$5.69M Buy
3,233,150
+1,828,004
+130% +$5.22M ﹤0.01% 3585
2022
Q4 		$4.41M Buy
1,405,146
+976,491
+228% +$3.79M ﹤0.01% 4068
2022
Q3 		$2.1M Sell
428,655
-195,848
-31% -$1.01M ﹤0.01% 5498
2022
Q2 		$2.58M Buy
624,503
+112,295
+22% +$486K ﹤0.01% 5035
2022
Q1 		$2.98M Sell
512,208
-149,208
-23% -$887K ﹤0.01% 5207
2021
Q4 		$4.96M Buy
661,416
+267,306
+68% +$2.32M ﹤0.01% 4309
2021
Q3 		$3.55M Sell
394,110
-395,059
-50% -$3.91M ﹤0.01% 4996
2021
Q2 		$9.45M Sell
789,169
-465,554
-37% -$5.27M ﹤0.01% 3172
2021
Q1 		$15.7M Buy
1,254,723
+653,646
+109% +$8.81M ﹤0.01% 2296
2020
Q4 		$9.38M Sell
601,077
-740,273
-55% -$8.67M ﹤0.01% 2728
2020
Q3 		$12.7M Buy
1,341,350
+992,494
+284% +$10.7M ﹤0.01% 2010
2020
Q2 		$3.13M Sell
348,856
-1,141,963
-77% -$10.6M ﹤0.01% 3786
2020
Q1 		$9.5M Buy
1,490,819
+525,400
+54% +$3.9M ﹤0.01% 1911
2019
Q4 		$8.08M Sell
965,419
-1,224,096
-56% -$11.3M ﹤0.01% 2458
2019
Q3 		$19.8M Buy
2,189,515
+282,533
+15% +$3.17M 0.01% 1477
2019
Q2 		$20.5M Buy
1,906,982
+1,650,290
+643% +$17.6M 0.01% 1402
2019
Q1 		$2.45M Buy
256,692
+73,255
+40% +$748K ﹤0.01% 4117
2018
Q4 		$2.11M Sell
183,437
-329,924
-64% -$4.1M ﹤0.01% 4065
2018
Q3 		$8.7M Buy
513,361
+297,808
+138% +$4.53M ﹤0.01% 2284
2018
Q2 		$3.06M Sell
215,553
-1,637
-0.8% -$27.2K ﹤0.01% 3447
2018
Q1 		$4.13M Sell
217,190
-104,458
-32% -$2.23M ﹤0.01% 2674
2017
Q4 		$5.28M Sell
321,648
-42,747
-12% -$636K ﹤0.01% 2417
2017
Q3 		$5.47M Sell
364,395
-976,806
-73% -$10.8M ﹤0.01% 2220
2017
Q2 		$11.8M Buy
1,341,201
+1,306,303
+3,743% +$8.38M 0.01% 1336
2017
Q1 		$181K Sell
34,898
-84,802
-71% -$340K ﹤0.01% 6594
2016
Q4 		$365K Buy
119,700
+100,965
+539% +$368K ﹤0.01% 5394
2016
Q3 		$87K Buy
+18,735
New +$95.3K ﹤0.01% 6698
2016
Q2 		– Sell
-12,678
Closed -$80.8K – 7334
2016
Q1 		$77K Buy
12,678
+11,447
+930% +$68.7K ﹤0.01% 6129
2015
Q4 		$11K Sell
1,231
-37,163
-97% -$286K ﹤0.01% 8246
2015
Q3 		$217K Buy
+38,394
New +$317K ﹤0.01% 6038
2015
Q2 		– Sell
-64,010
Closed -$825K – 9052
2015
Q1 		$1M Sell
64,010
-101,272
-61% -$1.57M ﹤0.01% 3916
2014
Q4 		$2.51M Buy
165,282
+22,553
+16% +$274K ﹤0.01% 2653
2014
Q3 		$1.54M Sell
142,729
-25,964
-15% -$339K ﹤0.01% 3172
2014
Q2 		$2.58M Buy
168,693
+101,898
+153% +$1.47M ﹤0.01% 2492
2014
Q1 		$1.21M Sell
66,795
-3,887
-5% -$74.9K ﹤0.01% 3201
2013
Q4 		$981K Buy
70,682
+58,276
+470% +$671K ﹤0.01% 3244
2013
Q3 		$130K Buy
12,406
+2,556
+26% +$25.4K ﹤0.01% 5148
2013
Q2 		$77K Buy
+9,850
New +$85.9K ﹤0.01% 5407

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's SGMO Position: Q4 2025 in Review

Citadel Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,208,415 shares — an estimated $641K sold.

Citadel Advisors first reported a position in SGMO in Q2 2013 and held it in 48 quarters. The position peaked at $20.5M in Q2 2019. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Citadel Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,208,415 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $641K.
  • Citadel Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 48 quarters.
  • Citadel Advisors's SANGAMO THERAPEUTICS INC position peaked at $20.5M in Q2 2019.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.